ATE493495T1 - Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen - Google Patents

Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen

Info

Publication number: ATE493495T1
Authority: AT; Austria
Prior art keywords: dna vaccines; methods; genetely; engineered; production
Prior art date: 2000-09-08

Application number

AT01972985T

Other languages

English (en)

Inventor

David Hone

George Lewis

Timothy Fouts

Ken Bagley

Michael Boyson

Christine Obriecht

Mt Shata

Simon Agwale

Original Assignee

Univ Maryland Biotech Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-08

Filing date

2001-09-10

Publication date

2011-01-15

2001-09-10 Application filed by Univ Maryland Biotech Inst filed Critical Univ Maryland Biotech Inst

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE493495T1 publication Critical patent/ATE493495T1/de

Links

230000004186 co-expression Effects 0.000 title abstract 2
229960005486 vaccine Drugs 0.000 title 1
108010041986 DNA Vaccines Proteins 0.000 abstract 2
229940021995 DNA vaccine Drugs 0.000 abstract 2
108020005544 Antisense RNA Proteins 0.000 abstract 1
108090000994 Catalytic RNA Proteins 0.000 abstract 1
102000053642 Catalytic RNA Human genes 0.000 abstract 1
241001465754 Metazoa Species 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
230000001580 bacterial effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000004957 immunoregulator effect Effects 0.000 abstract 1
230000003071 parasitic effect Effects 0.000 abstract 1
244000052769 pathogen Species 0.000 abstract 1
108091092562 ribozyme Proteins 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT01972985T 2000-09-08 2001-09-10 Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen ATE493495T1 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US23137600P	2000-09-08	2000-09-08
US23140300P	2000-09-08	2000-09-08
US23107000P	2000-09-08	2000-09-08
US23144900P	2000-09-08	2000-09-08
PCT/US2001/028365 WO2002019968A2 (en)	2000-09-08	2001-09-10	Genetically engineered co-expression dna vaccines, construction methods and uses thereof

Publications (1)

Publication Number	Publication Date
ATE493495T1 true ATE493495T1 (de)	2011-01-15

Family

ID=27499592

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01972985T ATE493495T1 (de)	2000-09-08	2001-09-10	Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen

Country Status (6)

Country	Link
US (1)	US20020193330A1 (de)
EP (2)	EP2329846B1 (de)
AT (1)	ATE493495T1 (de)
AU (1)	AU2001292610A1 (de)
DE (1)	DE60143755D1 (de)
WO (1)	WO2002019968A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050226890A1 (en) *	1999-08-12	2005-10-13	Cohen David I	Tat-based vaccine compositions and methods of making and using same
US20080044435A1 (en) *	2004-03-16	2008-02-21	Cohen David I	Tat-Based Tolerogen Compositions and Methods of Making and Using Same
WO2004001035A1 (en) *	2002-06-21	2003-12-31	Centocor, Inc.	Method for generating monoclonal antibodies
US20040209362A1 (en) *	2003-03-19	2004-10-21	Stratagene	Electrocompetent host cells
EP1566439A1 (de) *	2004-02-20	2005-08-24	Nestec S.A.	Prophylaxe oder Behandlung von Obesitas
US7927580B2 (en) *	2004-03-16	2011-04-19	Nanirx, Inc.	Tat-based immunomodulatory compositions and methods of their discovery and use
WO2006078271A2 (en) *	2004-04-20	2006-07-27	The United States Of America As Represented By The Secretary Of The Navy	Cloning and expression of the full length 110 kda antigen of orientia tsutsugamushi to be used as a vaccine component against scrub typhus
CN100572541C (zh) *	2007-05-28	2009-12-23	中国农业科学院兰州兽医研究所	口蹄疫病毒双效疫苗载体、其制备方法及应用
EP2333091B1 (de)	2007-05-29	2017-06-21	Nature Technology Corporation	Vektoren und verfahren zur genetischen immunisierung
SG10201408162PA (en) *	2007-12-11	2015-01-29	Scripps Research Inst	Compositions and methods related to mrna translational enhancer elements
EP2350132A4 (de) *	2008-10-21	2013-05-29	Internat Vaccine Inst	Die a1-gruppe der a-untereinheit des choleratoxins als adjuvans für mukosale und systemische impfstoffe
EP2411043B1 (de)	2009-03-23	2013-07-31	PIN Pharma, Inc.	Krebsbehandlung mit immunstimulierenden hiv-tat-derivat-polypeptiden
WO2012000188A1 (en) *	2010-06-30	2012-01-05	Tot Shanghai Rd Center Co., Ltd.	Recombinant tumor vaccine and method of producing such
RU2603075C2 (ru)	2010-11-25	2016-11-20	Имнейт Сарл	Изменение иммуногенности антигена путем введения эпитопов, узнаваемых nkt-клетками
CA2819182C (en) *	2010-11-25	2021-06-29	Imnate Sarl	Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells
CN105705164A (zh)	2013-10-04	2016-06-22	品诺制药公司	用于癌症治疗的免疫刺激性hiv tat衍生多肽
CA3042321A1 (en)	2016-11-01	2018-05-11	Novo Nordisk A/S	Tolerogenic dna vaccine
US11419928B2 (en)	2017-10-25	2022-08-23	The Johns Hopkins University	Methods and compositions for treating cancer
US11279745B2 (en)	2019-04-26	2022-03-22	Novo Nordisk A/S	Tolerogenic DNA vaccine
CN115820713B (zh) *	2022-12-09	2024-10-22	天津大学	禽流感酵母疫苗重组载体和口服疫苗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4937190A (en) *	1987-10-15	1990-06-26	Wisconsin Alumni Research Foundation	Translation enhancer
US5703055A (en) *	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5416017A (en) *	1990-05-18	1995-05-16	The Scripps Research Institute	Cholera toxin gene regulated by tissue-specific promoters
IL101715A (en) *	1991-05-02	2005-06-19	Amgen Inc	Recombinant dna-derived cholera toxin subunit analogs
US5877159A (en)	1995-05-03	1999-03-02	University Of Maryland At Baltimore	Method for introducing and expressing genes in animal cells and live invasive bacterial vectors for use in the same
EP0803573A1 (de) *	1996-04-25	1997-10-29	Gesellschaft für Biotechnologische Forschung mbH (GBF)	Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe
US6589529B1 (en) *	1998-10-30	2003-07-08	Children's Hospital Medical Center	Rotavirus subunit vaccine
AU2002346249B2 (en) *	2001-06-07	2007-03-15	The Regents Of The University Of Colorado	Mutant Forms of Cholera Holotoxin as an Adjuvant

2001
- 2001-09-10 EP EP10007008.5A patent/EP2329846B1/de not_active Expired - Lifetime
- 2001-09-10 US US09/950,335 patent/US20020193330A1/en not_active Abandoned
- 2001-09-10 EP EP01972985A patent/EP1315816B1/de not_active Expired - Lifetime
- 2001-09-10 AT AT01972985T patent/ATE493495T1/de not_active IP Right Cessation
- 2001-09-10 AU AU2001292610A patent/AU2001292610A1/en not_active Abandoned
- 2001-09-10 DE DE60143755T patent/DE60143755D1/de not_active Expired - Lifetime
- 2001-09-10 WO PCT/US2001/028365 patent/WO2002019968A2/en not_active Ceased

Also Published As

Publication number	Publication date
AU2001292610A1 (en)	2002-03-22
EP1315816A2 (de)	2003-06-04
DE60143755D1 (de)	2011-02-10
EP1315816B1 (de)	2010-12-29
EP1315816A4 (de)	2006-05-17
WO2002019968A2 (en)	2002-03-14
EP2329846A1 (de)	2011-06-08
US20020193330A1 (en)	2002-12-19
EP2329846B1 (de)	2014-11-12
WO2002019968A9 (en)	2002-07-25
WO2002019968A3 (en)	2002-05-16

Legal Events

Date	Code	Title	Description
2011-06-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE493495T1 (de)	2011-01-15	Genmanipulierte dna-vakzine zur co-expression, methoden zu deren herstellung und deren verwendungen
DK1951296T3 (da)	2011-03-28	Celleafledte virale vacciner med lave niveauer af restcelle-DNA
PT1487485E (pt)	2011-03-11	Adjuvantes de imidazoquinolina para vacinas de adn
WO2003059381A3 (en)	2004-01-22	Immunogenic preparations and vaccines on the basis of mrna
ATE396739T1 (de)	2008-06-15	Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
EP4219566A3 (de)	2023-09-06	Rekombinante rsv-antigene
ATE485056T1 (de)	2010-11-15	Verbesserte impfstoffe
NZ593220A (en)	2012-10-26	Immunostimulatory oligonucleotides
DE60039198D1 (de)	2008-07-24	Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
DE60232647D1 (de)	2009-07-30	Vorrichtung zur abgabe einer vakzine
ATE521621T1 (de)	2011-09-15	Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
DE60336588D1 (de)	2011-05-12	Verbesserte anthraximpfstoffe und abgabeverfahren
DK1796717T3 (da)	2012-05-29	Kombinationsvaccine
DE60325838D1 (de)	2009-03-05	Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DE602004023196D1 (de)	2009-10-29	Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)
ATE505482T1 (de)	2011-04-15	Impfstoff gegen infektiöses lachsanämievirus
WO2005048918A3 (en)	2007-05-31	Anthrax vaccine
DK1074266T3 (da)	2007-04-10	Levende svækkede bakterier til anvendelse i vaccine
WO2004073604A3 (en)	2005-05-26	Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity
DK1740206T3 (da)	2011-10-17	PHEP, en aminosyrepermease af Staphylococcus Aureus
DE60238554D1 (de)	2011-01-20	Vakzine gegen infektionskrankheiten
TH95334A (th)	2009-04-30	การใช้ของวัคซีนสำหรับการรักษา/การป้องกันของการแพร่เชื้อของจุลชีพก่อโรค
DE602006018985D1 (de)	2011-01-27	Zusammensetzung mit einem kolloidalen synthetischen bioresorbierbaren vektor und einem viralen vektor
UA67251A (en)	2004-06-15	Strain paramixovirus-3 bovis "zksm" for the preparation of vaccines and diagnosticums
TH87147B (th)	2007-10-19	วัคซีนสำหรับการทำให้เกิดภูมิคุ้มกันที่ต้านเชื้อเฮลิโคแมคเตอร์